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ABSTRACT 
 The annual incidence of knee replacement (KR) procedures in the United 
States is predicted to reach over 3.5 million by the year 2030. KR is the current 
definitive treatment for debilitating knee osteoarthritis (KOA). There has yet to be 
substantial research regarding the impact of KR on participation in community 
activities and quality of life.  The hypotheses evaluated in this dissertation were 
that persons following KR will have 1) faster gait speed and 2) lower risk of 
participation restrictions than persons without KR; and 3) a decreased risk of all-
cause mortality compared to persons without KR. 
 To address the first two hypotheses, we collected data from subjects with 
KOA from the Multicenter Osteoarthritis Study and the Osteoarthritis Initiative, 
large cohorts of older adults with or at risk of KOA at the time of enrollment. In 
the first study, KR did not have an effect on gait speed overall and among most 
subgroups, however subjects with a slow gait speed prior to KR did have an 80% 
increased risk (RR 1.8, 95% CI 1.1, 3.0) of having a healthy gait speed compared 
with non-KR subjects. In the second study, KR was associated with a small 
decreased risk of having participation restriction (RR 0.82, 95% CI 0.67, 0.99). 
  vii 
 The third study used data on patients with KOA from the Clinical Practice 
Research Datalink, a database of clinical information on > 8 million people 
throughout the United Kingdom. There was a decrease in the death rate among 
KOA subjects who had a KR compared to those who did not, and the hazard of 
death was reduced by over one half in the first five years after the procedure (HR 
0.46 (95% CI 0.43, 0.51). For most subjects, this benefit did not extend longer 
than five years, and patients least likely to have KR (due to clinical and medical 
presentation) showed an increased hazard of death compared to the non-KR 
subjects. 
In conclusion, the results of this dissertation support the hypotheses that 
KR confers a positive benefit to activity and participation related pursuits which 
may extend to survival in the short term for some people. 
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1. INTRODUCTION  
Overview of Knee Replacement 
A1: Clinical Description 
Knee osteoarthritis has been characterized as total joint failure, that is, a complex 
degradation of articular and meniscal cartilage, bone marrow lesions, and 
osteophyte production in the knee. There is currently no known treatment for 
progressive or end-stage knee osteoarthritis. At this point in the disease process, 
knee pain is quite common, and joint effusion (swelling), deformities and 
weakness surrounding the knee may have developed. These impairments 
generally lead to pain and difficulty performing activities of daily living and social 
and community participation. Consequently, when knee osteoarthritis progresses 
to the degree that a person can no longer tolerate the pain or functional 
limitations imposed by the degenerative changes to the joint, many patients elect 
to undergo a knee replacement. A knee replacement typically consists of the 
removal of all three compartments of the knee joint (medial, lateral, and 
patellofemoral) by removing the articulating ends of the femur and the tibia, as 
well as the patella. These bony structures are then replaced by synthetic 
materials such as titanium and plastic which are fixated to the existing bone by 
cement or bony ingrowth. This invasive procedure requires a comprehensive 
peri-surgical and post-surgical medical and rehabilitation program which can last 
for many months following the procedure. 
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A2. Knee Replacement Epidemiology 
The annual incidence of knee replacement procedures in the United States (US) 
is predicted to reach over 3.5 million by the year 20301. This projected rapid 
increase may reflect both the aging of and increased prevalence of obesity in the 
population2, both strong risk factors for knee osteoarthritis3 and potentially 
patients’ desire to continue to be active into the later years of life. Knee 
replacement (KR) is presumed to allow patients to return to an active lifestyle, 
however, recent evidence shows that 10-30% of patients are dissatisfied or have 
pain and functional activity limitations persisting at least 2 years after knee 
replacement4,5. Therefore it is likely that a large number of Americans undergoing 
this highly invasive surgical procedure will continue to have limitations, and is 
therefore an escalating US public health problem. 
Research on knee replacement outcomes has typically focused on surgical 
complications, the survival of the implant6, clinical impairments (e.g. pain or 
weakness7), and functional tasks (e.g. getting up from a chair or climbing stairs8). 
There has yet to be substantial research regarding the impact of the procedure 
on major functional activities or the ability of recipients of knee replacement to 
participate in activities in the community. 
 
A3. Knee replacement outcomes in the context of Health and Disability 
The International Classification of Functioning, Disability and Health (ICF) model9 
defines and describes the domains of health and disability as well as the 
  3 
relationships between the domains as shown in Figure 1.1. The three main 
domains are Body Structure and Function, which represent one’s anatomical and 
physiological systems; Activities, which encompass functions such as getting out 
of a chair or climbing a step; and Participation, defined as “involvement in life 
situations”. While the underlying health condition and personal factors can impact 
all three of the major domains concurrently, the alignment of the domains from 
left to right signifies the increasing complexity of human tasks relevant to their 
health or disability status. Therefore, this model provides a biopsychosocial 
framework for research investigating the effect of knee replacements on a 
person’s health status at various points on the continuum between the body’s 
structure and function and one’s participation in social and community activities.  
In the context of a person with knee osteoarthritis having a knee replacement, 
knee osteoarthritis is the health condition, and the body function and structure 
are those impairments that typically follow a knee replacement such as knee 
pain, limited knee range of motion, and lower extremity weakness. These 
impairments may or may not be improved after knee replacement, and have 
been the subject of much research.  The outcomes of knee replacement that 
concern the domains further along the model, specifically in the Activity and 
Participation domains are less understood, and are studied in this dissertation. 
As recent literature has suggested that improvements in pain and function may 
continue for more than one year following knee replacement10, and we are 
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interested in outcomes at the furthest end of the ICF model, we measured our 
outcomes at least one year after surgery.  
                    
A4. Confounding by indication in knee replacement studies 
Conducting a randomized trial of knee replacement outcomes is currently unlikely 
due to the inherent risks associated with an invasive surgery, leading to a lack of 
equipoise between treatment groups. Therefore, studies of knee replacement 
outcomes are generally restricted to knee replacement subjects or include a 
control group of subjects that did not have a knee replacement. This raises the 
potential for confounding, as there are likely to be differences between the 
subjects that undergo the knee replacement compared with those who do not, 
and these differences may be associated with the knee replacement status and 
the outcome of interest. As knee replacement is a treatment for end-stage knee 
arthritis, it is open to similar threats to confounding as other studies of 
treatments, in particular confounding by indication. This occurs when the 
treatment (or exposure) could be considered a marker for another variable that is 
associated with having the exposure and also associated with the outcome under 
study.11 A knee replacement is an elective procedure, therefore there are many 
factors associated with making this choice that may also be associated with the 
outcome under study. For example, positive or less positive psychosocial factors 
could influence whether one decides to undergo a knee replacement. Similarly, 
these factors could be associated with many health-related outcomes after the 
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surgery. However, the general health and ability to tolerate surgery may be the 
chief concern about confounding by indication when one considers bias in a 
study of knee replacement outcomes. If the underlying health status is 
associated with whether one elects a knee replacement and also associated with 
the outcome, it may be their health status, not the knee replacement that is 
actually responsible for the estimate of effect. 
There are many methods to counteract the effect of confounding by indication, 
with the main goal of increasing similarities between the exposure and 
comparison groups. In this dissertation we use two approaches: propensity 
scores and adjustment for severity of covariate constellations. The propensity 
score approach calculates the probability of the exposure for each subject based 
on their unique covariate profile12. The propensity scores can then be used in a 
statistical model, or can be used to match exposed and unexposed subjects. 
Using one number representing the impact of all covariates as opposed to a 
comprehensive list of covariates can increase the efficiency of statistical 
methods.  
In the second approach we attempt to classify important covariates based on 
their severity as many clinical diagnoses have a continuum of expression that 
may lead to bias if unaccounted for. When available, clinical guidelines and 
literature were used to construct algorithms to classify disease severity. These 
categories were then used in the statistical models to account for differences 
between exposure groups.  
  6 
In summary, with increasing longevity and numbers of persons undergoing knee 
replacement, it is important to understand outcomes of this procedure on 
activities and personal and community activities further towards the extreme of 
the health and disability model. 
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Figure 1.1. International Classification of Functioning, Disability and Health9         
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2. The effect of knee replacement on gait speed among persons with 
symptomatic knee osteoarthritis 
2.1 INTRODUCTION  
Gait speed is a measure of functional activity that has been associated with 
health outcomes, including cardiovascular morbidity and mortality1,2. A large 
prospective study of older adults found that a habitual gait speed of less than 1 
meter per second (m/s) was highly predictive of adverse health outcomes such 
as severe lower extremity limitation, hospitalization, and death2. Gait speed is a 
complex measure of the cardiovascular and neuromuscular systems, and there is 
evidence that gait speed can be successfully modified with intervention, typically 
physical therapy, including among people with knee osteoarthritis3. While it is not 
possible to guarantee good health outcomes from improvement in gait speed, 
data suggest incremental changes in risk occur with changes of 0.1 m/s in gait 
speed1. 
Despite the important associations between gait speed and health outcomes, 
and the vital role of the knee joint in gait for both range of motion and stability, 
there is surprisingly little research on the effects of knee replacement on gait 
speed. As the number of knee replacements performed annually in the US is 
expected to reach 3.5 million by 20304, the public health impact of gait speed 
after knee replacement is far-reaching. If knee replacement results in faster gait 
speed compared with pre-knee replacement speed, this could have implications 
on quality of life, as well as on diseases associated with both gait speed and 
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positive health outcomes, such as cardiovascular disease. To date, most studies 
of gait speed after knee replacement did not have a comparison group, or 
compared the gait speed of knee replacement subjects to healthy control 
subjects5-10. These studies were threatened by confounding by indication from 
differences between persons who choose to have knee replacements and those 
that do not. For example, persons who have knee replacement may have less 
co-morbidity, allowing them to safely undergo the surgery, which would favorably 
bias the outcomes of the knee replacement subjects. On the other hand, persons 
with knee replacement are likely to have worse prior function, which is associated 
with post-knee replacement function11-13, and they therefore may be more likely 
to have a slower gait speed than a healthy comparison group. Therefore, it is 
critical to use a comparison group of subjects with knee osteoarthritis and to use 
methods that address the potential confounding by indication such as matching 
on functional status and comorbidities to allow for a more accurate estimate of 
the effect of knee replacement on gait speed.  
To that end, the purpose of the current study was to assess the effect of knee 
replacement on gait speed using a comparison group with symptomatic knee 
osteoarthritis from the same study sample from which the knee replacement 
subjects arose, and matching on the propensity to undergo a knee replacement.   
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2.2 METHODS 
2.2.1 Study Sample 
The study sample was selected from subjects from the Multicenter Osteoarthritis 
Study (MOST) and the Osteoarthritis Initiative (OAI) cohorts.  MOST is a 
longitudinal cohort study consisting of 3026 subjects aged between 50-79 at 
enrollment who were recruited from the community in the Iowa City, Iowa and 
Birmingham, Alabama regions with or at risk of developing knee osteoarthritis, 
and who did not have cancer, were able to walk independently, and were not 
planning on moving outside the study area in the following few years. Subjects 
attended clinic visits at baseline, 30, 60, and 84 months. OAI is a similar 
longitudinal cohort with 4796 subjects aged 45-79, recruited from the Baltimore, 
Maryland, Pawtucket, Rhode Island, Columbus, Ohio, and Pittsburgh, 
Pennsylvania regions. Both cohorts collected comprehensive demographic, 
clinical, and imaging data.  We included all subjects from either cohort who 
reported symptomatic knee osteoarthritis (SxOA), defined as pain in the knee on 
most of the last 30 days and radiographic evidence of knee osteoarthritis, during 
one or more clinic visit. Subjects with gait speed measured at least 12 months 
following the index date were included in our analyses (described below).  
2.2.2 Study Design 
This is a longitudinal cohort study. We conducted analyses on two samples from 
the study population: 1) we randomly selected four unexposed (non-KR) subjects 
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for every one exposed subject (KR) from the pool of non-KR subjects that 
reported SxOA at the clinic visit prior to the calendar date of the KR. This sample 
we call the baseline visit matched sample, and is used for crude analyses. 2) We 
also conducted analyses on a sample of subjects where each KR subject was 
matched to one non-KR subject by propensity score to reduce the effect of 
confounding by indication. In both samples, for each matched set, baseline 
covariate data was collected from the clinic visit prior to the calendar date of the 
KR for that subject in each matched set. The outcome data was collected from 
the first clinic visit that occurred ≥ 12 months after the calendar date of the KR 
(Figure 2.1) in each matched set, henceforth referred to as the “outcome visit”.  
2.2.3 Measurement of Variables 
2.2.3.1 Dependent Variable 
Our primary outcome was gait speed. Gait speed was measured at every clinic 
visit in MOST and at the 12, 24, 36, 48, and 72 month visits in OAI. In both 
cohorts, subjects participated in a 20-meter walk test and the time to complete 
the test was converted to gait speed, in m/s. Based on literature pertaining to the 
effect of gait speed on health outcomes1,2, we also dichotomized gait speed into 
‘slow’ for speeds < 1.0 m/s and ‘healthy’ for speeds ≥1.0 m/s. To allow for 
surgical recovery, we used the first gait speed measured at the clinic visit closest 
to but at least 12 months after the date of the KR as the primary outcome (Figure 
2.1). 
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2.2.3.2 Independent Variable 
Our primary independent variable was knee replacement. The exposed group 
consisted of persons with symptomatic knee osteoarthritis in either study that 
underwent only one unilateral primary knee replacement post- enrollment. In the 
MOST Study, knee replacement status was determined by self-report at each 
clinic visit or at the 15-month telephone contact visit, and over 95% percent of 
knee replacements were additionally confirmed by medical record or 
radiographs. In OAI, knee replacements were similarly confirmed. Subjects with a 
knee replacement reported at study enrollment were excluded. We further 
excluded subjects who had more than one knee replaced between study 
enrollment and the time of the outcome assessment. 
2.2.3.3 Potential Confounders: Potential confounders of the association 
between knee replacement and gait speed included: sex, age at knee 
replacement, race, comorbidities (modified Charlson comorbidity index14), 
depressive symptoms (score of >=16 on Centers for Epidemiologic Studies 
Depression Scale (CES-D)15), body mass index, and time from KR date to gait 
speed assessment. Potential confounders were assessed for association with 
knee replacement and those with a p-value of <0.20, were adjusted for using 
propensity scores.  
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2.2.4 Statistical Analysis 
Among the baseline visit matched sample, we calculated the mean gait speed for 
the knee replacement and non-knee replacement groups at the outcome visit and 
compared them using a t-test. We further stratified by sex, age (< or ≥ 65 years 
old), race (White versus non-White), and number of comorbidities (≤1 or > 1). We 
calculated the proportion of subjects in each stratum with healthy gait speed (>1 
m/s) at the outcome visit. We estimated the association between  knee 
replacement status and gait speed by generating risk ratios (RR) and 95% 
confidence intervals (CI) using a regression analysis with robust variance 
estimation approach18. 
To attempt to control for confounding, we used a propensity score matching 
approach. We first generated a list of variables collected in the MOST and OAI 
cohorts thought to be predictive of knee replacement from previous literature. We 
conducted univariable analyses to assess the relation between each candidate 
variable and the exposure (having a knee replacement). Variables associated 
with knee replacement (p-value < 0.2, Table 2) were entered into a logistic 
regression model to estimate a propensity score for each subject signifying the 
probability of having a knee replacement given the covariates. We evaluated the 
propensity scores for the exposed and non-exposed groups for adequacy of 
overlap (with a standardized difference score of < 10% indicating balance 
between groups16). We then matched the non-knee replacement subjects to the 
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knee replacement subjects 1:1 by propensity score using a greedy match 
algorithm. In greedy matching exposed subjects are matched to the first non-
exposed subject nearest to its propensity score, starting with five digits, then 
deceasing as needed, within a pre-specified caliper width (0.02)17. After the 
match is made, other unexposed subjects become ineligible to be matched to 
that exposed subject. We evaluated the effect of knee replacement status on the 
risk of healthy gait speed after matching on propensity score again using 
regression analysis with robust variance estimation approach18. In addition to 
stratifying on demographic and clinical variables of interest as above, we also 
stratified the matched model by baseline gait speed (< and ≥1 m/s), as it could be 
an important confounder. We assessed the association of knee replacement and 
gait speed by calculating the change from baseline to outcome visit by 
subtracting the latter from the former, and used t-tests to compare the means 
between knee replacement groups overall and within subgroups.  To test our 
propensity score matching approach, we also performed a sensitivity analyses 
among the baseline visit matched sample.  We first performed the analysis 
including all the covariates that made up the propensity score as covariates, and 
then repeated the analysis adjusting for only the covariates that were associated 
with both knee replacement and gait speed using the change-in-estimate 
approach. Both of these analyses generated risk ratios for the risk of healthy gait 
speed among the knee replacement subjects compared with the non-knee 
replacement subjects using a regression model with a robust error variance. 
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2.3 RESULTS  
2.3.1 Crude results: There were 360 subjects with symptomatic knee 
osteoarthritis and knee replacement (217 from MOST and 143 from OAI) and 
1436 (868 from MOST and 568 from OAI) with symptomatic knee osteoarthritis 
and no knee replacement in the baseline visit matched sample. These results are 
presented in Table 1. The knee replacement subjects were younger, had a 
higher proportion of White subjects, lower mean knee pain severity and walked at 
a slower speed than the non-knee replacement subjects. There was no 
difference in mean gait speed between the knee replacement and non-knee 
replacement subjects (mean difference -0.04 m/s (95% CI -0.07, 0.01). The 
proportion of subjects with healthy gait speed in each group was also similar, 
with a difference of -0.4% (-0.6, 0.5). 
2.3.2. Propensity score matched results: There were 299 subjects in each 
knee replacement group after matching by propensity score (184 from MOST 
and 115 from OAI). Subjects did not receive a propensity score (33 from MOST 
and 28 from OAI) due to missing data for some of the variables included in the 
model. Table 2.2 lists the variables that predicted knee replacement and thus 
were included in the propensity score model for each cohort. After matching, all 
variables were well-balanced with < 10% difference between the knee 
replacement and non-knee replacement subjects (Table 1).  However, we also 
included depressive symptoms in the final model since the difference between 
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groups was larger than for the other covariates and differed in direction than from 
the unadjusted sample. Figure 2.2 displays the overlap in propensity scores 
between exposure groups for each cohort. At the outcome visit, there was no 
difference between exposure groups for the mean gait speed overall, or within 
each subgroup (Table 2.3). The non-White and less healthy subgroups had the 
slowest mean gait speed, while males had the fastest. The mean gait speed 
exceeded the 1.0 m/s “healthy” cut-point in all our subject subgroups. However, 
there were a proportion of subjects in each subgroup that did not reach this 
benchmark (Table 2.4). Approximately 83% of the subjects in each knee 
replacement group met our definition for “healthy” gait speed. In most subgroups, 
the proportion with healthy gait speed was higher for the knee replacement 
subjects with the exception among non-Whites and the younger subjects. There 
was no effect of knee replacement group and the risk of having healthy gait 
speed (RR 1.0 (95% CI 0.93, 1.08) overall, or in any subgroup. However, when 
we stratified by presence or absence of healthy gait speed at baseline, there was 
an effect of knee replacement on having healthy post-KR gait speed for the 
subjects with slow gait speed prior to surgery (RR 1.8, 95% CI 1.1, 3.0). There 
was no effect for the subjects with healthy gait speed prior to surgery (RR 0.96, 
95%CI 0.91, 1.0). The change in gait speed from pre-KR to post-KR was 
minimal, with a mean increase of 0.012 (95% CI -0.7, 0.8)) m/s for the KR 
subjects and a mean decrease of 0.007 (95% CI -0.7, 0.5) m/s for the non-KR 
subjects. However, when the KR subjects were stratified by baseline gait speed 
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status, those with healthy gait speed pre-KR had a mean decrease in speed of 
0.014 (95% CI -0.7, 0.4) m/s, while those with slower than healthy gait speed had 
a clinically significant mean increase of 0.14 (-0.2, 0.8) m/s. The non-KR subjects 
had smaller changes than the KR subjects, with those with baseline healthy gait 
speed having a decrease of 0.02 m/s (95%CI -0.7, 0.4) and those with a baseline 
slow gait speed having an increase of 0.05 m/s (95% CI -0.4, 0.5). 
Our sensitivity analyses yielded similar results to the main analyses. When all the 
variables that were included in the propensity score were instead adjusted for in 
the model, we again found no association between knee replacement and gait 
speed, with a quite similar estimate (RR 1.05 95% CI 0.96, 1.14).  When we 
limited the adjustment to variables thought to be potential confounders due to 
their univariable associations with both knee replacement and gait speed (sex, 
race, number of comorbidities, depressive symptoms, and body mass index 
(BMI)), this also showed no association between knee replacement status and 
having a healthy gait speed (RR 0.96, 95% CI 0.89, 1.04) but it was shifted 
slightly toward a protective effect.  
 
2.4 DISCUSSION 
This study is the largest we know of that compares gait speed in subjects with 
SxOA who underwent knee replacement to those who did not. We performed a 
crude analysis, adjusted by propensity score, adjusted by potential confounders, 
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and explored the effects of gait speed measured both as a continuous and 
dichotomous variable. In general, the results indicate a lack of association 
between KR and gait speed ≥ 1 year later compared with a similar group with 
knee osteoarthritis but no KR. If gait speed is truly a marker of disability as 
shown in previous literature1,2, the present findings suggest that KR may not in 
fact reduce disability, perhaps only with respect to gait speed or activities 
associated with gait speed. However, the findings also suggest that among 
people with slow gait speed prior to the procedure, KR may be beneficial in 
reducing disability, as these subjects achieved a clinically meaningful 
improvement in gait speed for health outcomes. This could be important in 
decision making when determining which patients or at what point in the 
osteoarthritis disease process a patient should undergo knee replacement. 
Our overall results are consistent with smaller studies which have reported no 
mean difference in gait speed between knee replacement and non-knee 
replacement subjects8,9. However, our results contradict other studies that found 
a slower gait speed among knee replacement subjects7,10. As our study used a 
comparison group matched to the knee replacement subjects by propensity 
score, the comparison subjects in this study may have been more functionally 
limited and therefore walked slower than those in previous studies. 
There is a trend in clinical practice for knee replacement to be performed on 
younger patients19. Given this trend, we explored the effect of knee replacement 
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on gait speed as a continuous variable, as the cut-point of 1.0 m/s may be too 
slow to find an effect among the younger, better functioning subjects.  Stratifying 
our analyses by age category explored this further. However, our results do not 
suggest that younger subjects who have a KR achieve a faster gait speed than 
those who do not have a KR. It is possible that gait speed does not decline 
rapidly among young knee osteoarthritis patients. This hypothesis is supported 
by the very high percentage of all subjects < 65 years of age who walked at a 
healthy gait speed.  
To our knowledge, this is the first study to investigate the proportion of subjects 
attaining a “healthy” cut-point of 1 meter per second gait speed among knee 
replacement subjects, and has illuminated certain subgroups of knee 
osteoarthritis and knee replacement subjects that may be at risk for future poor 
health outcomes. The mean gait speeds for both treatment groups were higher 
than the cut-point of 1 m/s commonly cited as a marker for disability. However, 
approximately 17% of all subjects walked slower than the cut-point, and this 
proportion was much higher among some subgroups. For example, over 20% of 
the women and subjects over 65 years old walked slower than 1.0 m/s, whether 
or not they had their knee replaced. Over 30% of the non-White subjects and 
those with ≥ 1 comorbidity walked slower than 1.0 m/s. Interestingly, this 
proportion was higher among the non-White subjects who had a knee 
replacement compared to those who did not. This information is important for 
patients as well as for health care providers who discuss post-surgical 
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expectations with their clients.  This data also suggests that certain subgroups of 
patients with osteoarthritis and/or knee replacement may benefit from additional 
or specialized rehabilitation to optimize their walking speed and reduce their risk 
of poor health outcomes.  
Limitations 
Despite our use of propensity score matching, there exists the possibility of 
residual confounding from variables that were not collected in the cohort studies 
used. Choosing to have a knee replacement is a complex decision between a 
patient and their health care providers, leading to the concerns about 
confounding by indication. It is therefore not possible to control for all the 
potential variables that go into a person’s decision such as psychosocial factors 
other than depression, nor were all of these variables necessarily measured in 
MOST and OAI. Given the comprehensive personal and family history and 
clinical data collected in these databases, however, the impact of any 
confounding by unmeasured variables is likely to be reduced. The small change 
in the estimate of effect from the crude to the adjusted analyses also suggests 
that measured confounding was not strong issue in this study. This proposes that 
contrary to our initial concerns, the non-adjusted association did not appear to be 
confounded by variables that were associated with one’s probability of having a 
knee replacement, such as number of comorbidities, depressive symptoms, or 
pain.  
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Our adjusted sample size was lower than the crude, with 299 matched pairs in 
our analyses due to missing data for some of the variables included in the 
propensity score model (e.g. history of stroke). When these variables were 
removed, the balance between exposure groups declined. As our goal was to 
produce a comparison group as similar to the knee replacement group as 
possible, we chose to retain the original propensity score model. We did not 
perform multiple imputation because we did not feel doing so would have 
improved the balance between groups and since the data did not satisfy the 
“missing at random” condition required for multiple imputation. 
The propensity score approach is sometimes criticized due to the inclusion of 
variables associated with the exposure but not necessarily the outcome, which 
could lead to over-adjustment for confounding. To address this possibility, we 
performed sensitivity analyses using the whole sample adjusting for all covariates 
that were included in the propensity score, as well as adjusted for just the 
covariates that were also associated with the outcome of gait speed. These 
analyses also yielded no association, therefore we can be confident in our 
results. 
The number of staged (bilateral knee replacements performed in close 
succession) or concurrent bilateral knee replacements being performed today is 
high and continues to grow given the bilateral nature of knee osteoarthritis and 
improved perioperative care20. Concurrent bilateral knee replacements were not 
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included in the current study due to the complex visit structure of the cohorts 
used. Future studies should investigate the impact of bilateral knee replacements 
on gait speed. Additionally, we do not have data on the amount or type of post-
operative rehabilitation the knee replacement subjects or the symptomatic knee 
osteoarthritis groups may have had during the follow up time. While we may 
surmise that the knee replacement group may walk faster if they had recent post-
knee replacement physical therapy, our results can only demonstrate that after 
≥12 months, there is no difference between the two groups. Future work is 
needed to explore differences in rehabilitation utilization between these two 
groups and the trajectory of gait speed following the end of supervised care. 
Also, the gait speed differences between groups and between subjects pre- and 
post-KR could be small given the short distance of the 20 meter walk test and 
may not be as sensitive to change as a longer walk test, such as the Six Minute 
Walk Test. Finally, and not trivially, faster gait speed may not in fact increase 
health outcomes in the knee replacement population, and should be studied 
further. 
Conclusion: Persons at least one year following knee replacement do not 
demonstrate faster gait speeds or a higher proportion with a healthy gait speed 
as compared with similar subjects with symptomatic knee osteoarthritis who do 
not undergo knee replacement. However, there may be a benefit of KR on having 
healthy or increased gait speed for those with slow gait speed at baseline. The 
proportions with gait speed < 1 meter per second, commonly thought to increase 
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the risk of poor health outcomes, is approximately 17% at least one year after 
knee replacement, and is considerably higher for women, subjects older than 65, 
non-White subjects (especially those having a KR) and those with more than one 
comorbidity. This suggests a need for increased surveillance and/or intervention 
in these special populations of patients.  
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Table 2.1. Baseline demographic and clinical information for knee replacement 
(KR) and non- knee replacement (Non-KR) stratified by sample 
 
 
 
Variable 
Baseline Visit Matched 
Sample  
Propensity Score Sample 
 
KR  
subjects 
(n=360) 
Non- KR 
subjects 
(n=1436) 
KR  
subjects 
(n=299) 
Non- KR 
subjects 
(n=299) 
Age, years, mean (SD*) 
% <65 years old 
66.5 (8.1) 
41 
68.3 (7.8) 
42 
66.3 (8.1) 
42 
66.2 (8.7) 
42 
% Female 63 62 63 61 
% White 85 76 88 91 
BMI, kg/m
2
, mean (SD) 31.6 (6.2) 31.2 (6.1) 31.1 (5.8) 31.5 (6.2) 
Depressive score, range 
0-16, mean (SD) 
7.4 (6.9) 7.7 (7.6) 7.1 (6.9) 6.2 (6.6) 
% with ≤ 1 Comorbidity 84 85 84 85 
Knee pain, range 0-20,  
Mean, median 
4.3 (4.0) 6.4 (6.0) 6.3 (4.5) 5.8 (4.1) 
Gait speed, m/s, mean 
(SD) 
1.13 (0.21) 1.20 (0.22) 1.15 (0.20) 1.16 (0.21) 
*(SD) = standard deviation 
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Table 2.2 Variables retained in the propensity score model, stratified by cohort.  
MOST OAI  
Age Age 
Sex Sex 
Race Race 
Employment/Income Employment/Income 
Depressive symptoms Depressive symptoms 
Use of analgesics Use of knee pain medication 
Use of COXII inhibitors Use of COXII inhibitors 
Systolic Blood Pressure Systolic Blood Pressure 
SF-12* role physical score  SF-12 role physical score  
Baseline gait speed Baseline gait speed 
Worse WOMAC** Physical Function SF-12 Role Mental score 
Clinic Site Use of glucosamine 
Educational attainment Use of chondroitin 
Marital status Use of narcotics 
Presence of widespread pain History of heart failure 
Pack year history of smoking Worse WOMAC pain score 
Worse WOMAC total score Worse WOMAC function score 
Decreased knee flexion strength Diastolic blood pressure 
 Body mass index 
 Diabetes 
 History of knee injection 
 History of stroke 
*SF-12: Short Form 12 
**WOMAC: Western Ontario McMaster University Arthritis Index 
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Figure 2.1. Example of subject selection for each analysis, MOST cohort 
a. Unadjusted: A subject reports having a KR 37 months after enrollment. 
We used their 30-month visit data for the “baseline” data and the 60 month 
visit data (first visit ≥12 months from the calendar date of the KR, the 
“outcome visit”) for their outcome. We then selected 4 subjects who met 
the definition of SxOA at 30 months (the “baseline visit”) and had outcome 
data at the 60 month visit. The baseline and outcome data for these four 
subjects was selected from the same clinic visits as the KR subject.   
b. Adjusted: One SxOA subject was matched to one KR subject by their 
propensity score. As above, the baseline data was selected from the visit 
just prior to the calendar date of the KR (“baseline visit” and the outcome 
data was selected from the first clinic visit ≥12 months from the calendar 
date of the KR (“outcome visit”). 
  
0 month visit        30 month visit                60 month visit                  84 month visit 
 
                                             KR calendar date  
                           (Baseline visit)                (Outcome visit)                        
Notes: 
• if the first clinic visit after the calendar date of the KR is < 12 months 
following the surgery, outcome data was not selected from that visit. It 
was taken from the first clinic visit that fell ≥12 months from the KR 
date to allow for surgical recovery. 
• In OAI, the subject selection approach was the same, but the clinic 
visits occurred every 12 months.  
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Figure 2.2a. Overlap of propensity scores for probability of having a knee 
replacement for the knee replacement subjects (top) and non-knee replacement 
subjects (bottom) in the MOST cohort: i. prior to matching ii. following matching 
i.                   ii.                   
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Figure 2.2b. Overlap of propensity scores for probability of having a knee 
replacement for the knee replacement subjects (top) and non-knee replacement 
subjects (bottom) in the OAI cohort: i. prior to matching ii. following matching.  
i.         ii.               
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3. The association between knee replacement and participation restrictions 
among persons with symptomatic knee osteoarthritis 
 
3.1 INTRODUCTION 
Knee osteoarthritis is a leading cause of disability with estimates of 
approximately 10% of people over 55 years having disabling pain caused by 
radiographic degeneration1. These numbers continue to grow due to aging and 
increased obesity2,3. Currently, the only known effective intervention for end 
stage knee osteoarthritis is knee replacement, and consequently the number of 
persons undergoing this procedure is increasing rapidly, into the millions annually 
in the United States4. While there is evidence that knee replacements decrease 
pain and improve function for tasks such as getting out of a chair or putting on 
shoes in the vast majority of subjects5,6 there is surprisingly little evidence to 
determine whether knee replacement has any effect on home and community 
participation.  
  Participation, which is defined as “involvement in life situations”7, is a 
complex domain encompassing people’s roles and activities in their home and 
community. While participation is similar to functional activities, as participation in 
life roles often requires functions such as walking or rising from a chair, the two 
may not be related.  For example, persons with spinal cord injuries with functional 
impairments such as the inability to walk are often actively engaged in their 
occupation and community activities. On the other hand, other individuals without 
functional limitations might not participate in their home or community due to 
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psychosocial or environmental factors. In recent research, participation has been 
associated with both morbidity and mortality.8  
As the goal of knee replacement is to eradicate pain to improve quality of 
life, it is crucial to determine whether the procedure has an effect on engagement 
in life situations. Previous research in this area focused on limited aspects of 
participation such as the ability to perform activities of daily living or instrumental 
activities of daily living, such as cooking and doing light housework.9 In one such 
study, subjects with knee replacement improved in activities of daily living while a 
matched osteoarthritis group without knee replacement declined. Another study 
using a broad measure of home and community participation found that mean 
participation improved by 18% from 3 to 12 months post-knee replacement10. 
However, recent evidence showed that approximately 30% of subjects have 
participation restrictions greater than one year after knee replacement, and 
factors associated with participation restriction included depressive symptoms, 
older age and persistent pain in either knee11. Neither of the aforementioned 
studies had a comparison group, and therefore it is difficult to determine whether 
these participation restrictions could be completely accounted for by the knee 
replacement or whether these results are consistent with participation restrictions 
in the general population.  
Because of the limitations with the previous research, we sought to 
investigate the effect of knee replacement on participation compared to a 
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similarly matched group of subjects with symptomatic knee osteoarthritis that did 
not have a knee replacement. We hypothesized that persons with knee 
replacement have a lower risk of participation restrictions following surgical 
recovery (≥12 months) compared with a comparison group of persons with knee 
osteoarthritis who did not receive a knee replacement. We also hypothesized that 
persons with a knee replacement will have an improvement in participation 
scores over time, while the non-knee replacement subjects will not. Lastly, we 
hypothesized that there will be effect modification on the effect of knee 
replacement on participation, by age, presence of depressive symptoms, and 
race based on our previous work11.  
3.2 METHODS 
3.2.1 Study Sample 
The study sample was selected from subjects from the Multicenter Osteoarthritis 
Study (MOST) and the Osteoarthritis Initiative (OAI) cohorts.  MOST is a 
longitudinal cohort study consisting of 3026 subjects aged between 50-79 at 
enrollment who were recruited from the community in the Iowa City, Iowa and 
Birmingham, Alabama regions with or at risk of developing knee osteoarthritis, 
and who did not have cancer, were able to walk independently, and were not 
planning on moving outside the study area in the following few years. The OAI is 
a similar longitudinal cohort with 4796 subjects aged 45-79, recruited from 
Baltimore, Maryland, Pawtucket, Rhode Island, Columbus, Ohio, and Pittsburgh, 
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Pennsylvania regions. Both cohorts collect comprehensive demographic, clinical, 
and imaging data.  We included all subjects from either cohort who reported 
symptomatic knee osteoarthritis (defined as pain in the knee on most of the last 
30 days and radiographic evidence of knee osteoarthritis) during one or more 
clinic visit.  
3.2.2 Data Collection 
In the MOST cohort, data were collected at baseline, 30, 60, and 84 months, 
while in the OAI cohort data were collected annually up to 72 months.  
3.2.3 Study Design 
The design of this study was a matched cohort study. Exposed subjects were 
those with knee replacements (defined below) and the non-exposed were 
subjects with symptomatic knee osteoarthritis who did not undergo a knee 
replacement. We conducted our analyses on two samples from the study 
population. For crude analyses, we randomly selected four unexposed subjects 
for every knee replacement subject from the pool of non-KR subjects who 
reported symptomatic knee osteoarthritis at the clinic visit prior to the calendar 
date of the KR. We have labeled this the baseline visit matched sample. For 
adjusted analyses, each exposed subject was matched to one unexposed 
subject by propensity score (described below) and by having outcome data 
available at the first clinic visit that fell at least 12 months after the calendar date 
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of the knee replacement (outcome visit). Outcome data for both samples was 
ascertained from the outcome visit (Figure 3.1). 
3.2.4 Measurement of Variables 
3.2.4.1 Independent Variable 
Knee replacement: Exposed subjects were those who underwent only one 
(unilateral) primary knee replacement since study enrollment and who had a 
clinic visit at least 12 months after the knee replacement. Knee replacement 
status was determined by self-report at each clinic visit or at the 15-month 
telephone contact in the MOST Study. Over 95% percent of knee replacements 
were confirmed by medical record or radiographs. The unexposed group 
consisted of subjects with symptomatic knee osteoarthritis but without a knee 
replacement in either knee. 
3.2.4.2 Dependent Variable 
Participation: We used the instrumental limitation subscale of the disability 
component of the Late Life Function and Disability Instrument12 (LLDI-IL) to 
measure participation in this study. The Late Life Function and Disability 
Instrument is a well-validated tool that measures participation broadly across 
social, mobility-related, and management domains. The instrumental limitation 
subscale is comprised of 12 questions related to limitations in life roles requiring 
mobility and participation inside and outside of their home, such as “taking care 
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of personal shopping” or visiting friends in their home.  The LLDI-IL was collected 
at each visit in the MOST cohort, and at the 48-month and 72 month visits in the 
OAI cohort.  We used two measures of participation in this study: 1) participation 
as a continuous variable and 2) participation restriction, defined using an 
established cut-point for moderate-to-severe participation restriction of less than 
69 points.12,13 We also defined change in participation by calculating the 
difference between the LLDI-IL score at the outcome visit and the baseline visit.  
3.2.4.3 Potential Confounders: Sex, race, age, number of comorbidities, and 
depressive symptoms were considered potential confounders and/or effect 
modifiers of the association between knee replacement status and participation. 
We dichotomized age as < or ≥ 65 years old as the pre-Medicare population is 
the fastest growing segment of knee replacement patients14 and differences in 
outcomes between these groups may provide important information for potential 
interventions. Depressive symptoms were examined using the common cut-point 
of ≥16 on the CES-D15. Covariate data was taken from the baseline visit.  
3.2.4.4 Potential Intermediates: Persistent knee pain in the replaced knee may 
be a potential intermediate in the association between knee replacement and 
participation. Since this pain may be modifiable with intervention, we wish to 
examine its impact, and therefore, we stratified by the presence or absence of 
index knee persistent pain (defined using the Western Ontario McMaster 
  41 
Universities Arthritis Index (WOMAC) pain score of ≥1/20 vs. 0/20, 
respectively)16. 
3.2.5 Statistical Analysis 
As mentioned previously, we first matched four symptomatic knee osteoarthritis 
subjects to each knee replacement subject by pre-knee replacement (“baseline”) 
visit to create our unadjusted sample. To attempt to reduce confounding by 
indication, we calculated a propensity score for the probability of having a knee 
replacement for each subject in our sample given each subject’s covariate 
profile.  To build our propensity score model, we included covariates known to be 
associated with knee replacement in previous literature and that were associated 
with having a knee replacement in our sample with a p-value ≤0.20. To estimate 
a propensity score, these variables were included in a logistic regression model 
with knee replacement as the outcome (Table 3.1). Subjects with data missing 
for any of the variables included in the model were ineligible to receive a 
propensity score. We then matched each non-knee replacement subject to one 
knee replacement subject by propensity score and on outcome visit (first visit ≥ 
12 months from the calendar date of the KR) using a greedy and nearest 
available pair match approach17. The propensity scores for the exposed were 
ordered and matched to the nearest non-exposed subject, and this match was 
not reconsidered after matching17. We evaluated the effectiveness of matching 
on propensity scores by examining the balance among covariates in each group 
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using the standardized bias approach of dividing the difference in means or 
proportions by the standard deviation18. We used a conservative standardized 
bias value of 0.10 to indicate covariate balance18. We also graphed the 
distribution of the propensity scores for each knee replacement group both prior 
to and following the matching, to illustrate the change in overlap between scores 
(Figure 3.1). 
We conducted all analyses among both the unadjusted sample and propensity 
score (adjusted) sample. We calculated the mean participation score and the 
proportion of subjects in each exposure group with participation restrictions. 
These results were also stratified by sex, race, age (< or ≥ 65 years old), number 
of comorbidities (≤1 or > 1) and presence of depressive symptoms to assess for 
confounding or effect measure modification. We stratified by presence of 
persistent knee pain in the index knee to assess effect measure modification. As 
participation restrictions in this population are likely to be common, we evaluated 
the effect of knee replacement status on the risk of participation restriction 
(yes/no) by generating risk ratios and 95% confidence intervals (CIs) with 
regression using robust variance estimation approach.19 Then, we calculated the 
change in mean participation score of the outcome visit from the baseline visit 
and compared the differences between groups using 95% confidence intervals. 
Results were also stratified by sex, race, age (< or ≥ 65 years old), number of 
comorbidities (≤1 or > 1), presence of depressive symptoms, and persistent knee 
pain. To further investigate our hypothesis regarding change in participation over 
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time among exposure groups we plotted the mean participation score at each 
visit by knee replacement group in the MOST study, as participation was 
assessed at each clinic visit in this cohort.  
Sensitivity analyses: 
As the propensity score model accounted for variables that were associated with 
the exposure but not necessarily the outcome, this approach may include 
variables that are not actually confounders. We therefore repeated our analysis 
of the association between knee replacement status and participation restriction 
by controlling for the variables that were included in the propensity score model 
that were also associated with the outcome of participation restriction (by 
changing the unadjusted estimate by >10%). This was performed using a 
multivariable regression model to assess whether the results differed from the 
propensity score matched results. Increased time from the baseline visit to the 
date of knee replacement could result in less impaired participation pre-
exposure, particularly among the knee replacement subjects. This could bias our 
change analyses if this amount of time differed between exposure groups. 
Therefore we repeated the adjusted change analyses while restricting to those 
who had their baseline participation measured ≤6 months before the calendar 
date of the KR in the matched set as this could provide a closer estimate of the 
subjects’ pre-KR participation.  
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3.3 RESULTS  
There were 7071 subjects with symptomatic knee osteoarthritis in the two 
cohorts combined (2137 in MOST and 4934 in OAI). There were 371 subjects 
with one knee replacement and participation data at the first clinic visit at least 12 
months after the surgery (217 in MOST and 154 in OAI). The unadjusted results 
included 1484 symptomatic knee osteoarthritis subjects matched 1:4 to them. 
Table 3.2 presents demographic and clinical data for these subjects, as well as 
for the propensity score matched groups.  The propensity score models included 
the covariates listed in Table 3.2. Propensity scores were calculated for each 
cohort separately, as the predictors were different. There were 331 subjects in 
each exposure group after subjects were matched 1:1 by propensity score and 
the cohorts merged (192 from MOST and 139 from OAI). Twenty-three subjects 
from MOST and 15 from OAI failed to receive a propensity score due to missing 
covariate data. Two more knee replacement subjects from MOST did not receive 
a non-knee replacement match. When variables with missing data (in > 10% of 
cases) were removed from the propensity score model, the balance between 
exposure groups became worse. This indicated that these variables were 
important and should be included in our model, and as such were retained. Our 
knee replacement sample was similar to other studies as it was approximately 
2/3rd female, predominately White, and had high pain values. In the unadjusted 
sample, the knee replacement subjects were older, had more pain, were 
healthier, and more of them were White compared to the non-knee replacement 
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group, which was expected. After propensity score matching, baseline variables 
were more similar between groups, with all variables meeting our standardized 
bias criteria of 0.10 (Table 3.2) 
For the propensity score matched sample, outcome visit mean participation 
scores for the knee replacement group were 2.2 points higher (better) than for 
the non-knee replacement group. For all subgroups except the subjects with 
persistent knee pain, those who got knee replacement subjects had better 
participation than those who did not.  The largest mean difference in participation 
was found among subjects 65 and older where knee replacement was 
associated with a mean score 3.2 points higher than the non-knee replacement 
group (Table 3.3). 
 The proportion of subjects with outcome visit participation restriction (defined as 
<69/100 points on the LLDI-IL) in each exposure group, and the association 
between knee replacement status and participation restriction are presented in 
Table 3.4. There was a lower proportion of knee replacement subjects with 
participation restriction than subjects without knee replacement (35% vs. 43%, 
respectively), and there was a moderate overall protective effect of knee 
replacement on participation restriction (RR 0.82, 95% CI (0.67, 0.99)). There 
was effect measure modification on the association of KR status and participation 
restriction from some covariates. Having a knee replacement resulted in a 
protective effect on participation restriction for men, the younger subjects and 
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those without depressive symptoms, but was not effective among their 
counterparts (women, older subjects, those with depressive symptoms). When 
stratified by baseline participation restriction status, knee replacement was 
strongly protective against participation restriction among the subjects with 
participation restriction at baseline (RR 0.77, 95% CI 0.63, 0.93), while it was not 
associated with participation restriction (RR 1.2, 95% CI 0.73, 1.9) among those 
without participation restriction at baseline.  
To study change in participation (Table 3.5) we conducted a difference in 
differences analysis. We found that participation increased 1.4 points from 
baseline to the outcome visit among the knee replacement subjects, but declined 
by 0.5 points for the non-knee replacement subjects. Differences in change in 
participation from baseline to outcome visit were similarly small within subgroups 
for knee replacement compared to non-knee replacement subjects. Younger 
knee replacement subjects had the greatest mean change at 4.4 points. All knee 
replacement subgroups had an increase in participation except the older 
subjects, who experienced a decline. Conversely, all the non-knee replacement 
subgroups except women, the younger subjects, and surprisingly those with 
depressive symptoms had a decline in participation.  
Figure 3.2 graphically displays participation over time for each exposure 
group in the MOST cohort as the outcome was measured every visit in this study. 
In the matched sample, participation was similar in the two groups by the 
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baseline visit.  Following the date of the knee replacement, participation for the 
knee replacement group steadily improved, while it steadily declined for the non-
knee replacement group.  
Sensitivity analyses 
Race, body mass index, depressive symptoms, and knee pain, were all 
associated with having a knee replacement and with participation in univariable 
analyses and were therefore treated as possible confounders of the association 
between knee replacement status and participation in a regression analysis. Age 
was also included, although not associated with participation in this study. The 
analysis was performed in the full sample and then stratified by potential 
confounders (Table 3.6). The confidence intervals of each effect estimate 
included zero, and therefore there does not appear to be an association between 
knee replacement and participation using this method. When we restricted our 
change in participation analysis to those subjects who had their baseline 
participation measured within 6 months of the KR date, our results suggest a 
larger improvement in participation in the knee replacement group (mean change 
3.5 (-0.7, 7.6). The experience of the non-knee replacement subjects was similar 
to the main analysis, where there was a small decline in participation (-0.72, (-
2.9, 1.5)). 
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3.4 DISCUSSION 
In this study of 1484 subjects with knee osteoarthritis, we found that knee 
replacement was associated with a decreased risk of participation restriction 
compared to subjects who did not receive knee replacement. In particular, 
among subjects with participation restrictions at baseline, there was a strong 
protective effect against participation restriction for the knee replacement 
subjects compared with the non-knee replacement subjects. Mean participation 
improved after knee replacement, while it declined in non-knee replacement 
subjects, however the absolute changes did not reach significance. Despite the 
modest effects in the overall sample, the effect of knee replacement does appear 
to be stronger for various subsets of the population.  
Our main results are similar to a recent study that found a mean increase in 
participation from pre-knee replacement values10. However, as our study used a 
different scale of broad-scope participation, it is difficult to compare these two 
results directly. Further, as there is currently no valid measure of a minimal 
clinically important difference, it is difficult to characterize the clinical relevance of 
mean improvement. Given the psychometrics of the Late Life Disability 
Instrument Instrumental Limitations Subscale, it appears likely that a difference of 
≥ 4 points may be clinically meaningful. For example, this is equivalent to a one-
point change on the Likert scale for 4 out of the 12 items or a 4 point change on 
one item. These criteria would suggest that the younger subjects and those with 
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depressive symptoms made a clinically important improvement after knee 
replacement, and that the difference in improvement between knee replacement 
and non-knee replacement subjects was meaningful among males, the younger 
subjects, and non-Whites, with the knee replacement subjects having more 
improvement in participation.  As our study included a comparison group 
matched by propensity score, we are able to provide new information regarding 
the participation experience of both persons who undergo knee replacement as 
well as persons with symptomatic knee osteoarthritis that do not elect to have a 
knee replacement. Additionally, our approach allowed inspection of the 
proportion of subjects who met a fixed definition of participation restriction and 
the effect of knee replacement on participation restriction. Using this conservative 
measure of participation restriction, we found that a large proportion of persons 
after knee replacement and still a larger proportion with symptomatic knee 
osteoarthritis are limited with respect to participation domain activities. This, 
coupled with the small increases in participation overall and for most subgroups 
indicates that further research is necessary to explore ways to improve 
participation in the knee osteoarthritis and knee replacement populations.  
Perhaps the most clinically important finding is that the effect of knee 
replacement on participation restriction varies dependent on levels of other 
demographic and clinical variables. There was a decreased risk of participation 
restriction among males, subjects under the age of 65 years, and those without 
depressive symptoms that had a knee replacement compared to their 
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counterparts that did not. Although females with knee replacement had better 
participation than those without knee replacement, and had higher post-knee 
replacement participation than males, females had less of an increase in 
participation following the procedure than did males. This is partially consistent 
with studies of functional outcomes after knee replacement, where females tend 
to have a worse functional outcome and less functional improvement after knee 
replacement than men20. 
The results for the non-White subjects describe a less than positive participation 
outcome, which may provide a potential reason why non-Whites have lower 
utilization of knee replacement than Whites21. Both mean participation and the 
proportion with participation restrictions was worse among the non-White 
subjects compared to the White subjects; in fact, over half of the non-White knee 
replacement subjects had post-knee replacement participation restrictions. While 
we did not make direct comparisons between races, our results appear 
consistent with a study restricted to knee replacement subjects in which the non-
White subjects had 1.5 times the risk of participation restriction than Whites (RR 
1.5, 95%CI 0.7, 3.2)11. However, as only 12% of the subjects in the propensity 
score matched model were non-White, these results should be confirmed in a 
larger dataset. Disparities in health care utilization post-knee replacement could 
explain this finding, but to our knowledge has yet to be studied. 
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Regarding the younger subjects, it is important to characterize their participation, 
as the largest growing group of knee replacement patients is those less than 60 
years old14. Their mean participation rose the highest of any subgroup, except 
those with depressive symptoms, although still a third of them reported moderate 
to severe participation restrictions after knee replacement. Regarding those with 
depressive symptoms, although they had the largest amount of improvement 
after knee replacement, they also had the highest proportion with participation 
restrictions regardless of knee replacement status, at 70%. Subjects without 
depressive symptoms showed a protective effect of knee replacement on 
participation restriction. This suggests that additional interventions may be 
needed to address participation in those with symptomatic osteoarthritis and 
depressive symptoms, whether or not they choose to undergo a knee 
replacement. 
There are some limitations to this study. Missing data for some variables 
included in the propensity score model precluded those subjects from receiving a 
propensity score, reducing our sample size. However, we were successful at 
creating exposed and unexposed groups that were more similar to each other 
than in the whole sample, and this included comorbidities. This thereby allowed 
the examination of the effect of knee replacement on participation by using a 
control group that more closely represented the participation experience of the 
knee replacement subjects should they not have elected to undergo a knee 
replacement. The similarity of the matched propensity score and the crude 
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results may indicate a lack of or only weak confounding by the variables used in 
the propensity score model. Despite this, the possibility of residual confounding 
still exists.  Choosing to have a knee replacement is a very individual decision, 
and it is therefore not possible to include in the propensity score matching all the 
potential variables that go into each decision (or a surgeon’s recommendation), 
nor were all of these variables measured in MOST and OAI. Furthermore, some 
variables that may be confounders of the knee replacement and participation 
association, such as use of physical therapy services, were not collected in the 
MOST and OAI cohorts, and therefore their impact cannot be assessed. We 
stratified by persistent pain to assess any difference in effect between groups, 
which could lead to bias from conditioning on an intermediate. However, this bias 
should be toward the null if present22, and therefore would not change our 
conclusions. 
The results of our matching produced a comparison group that was healthier 
than the unadjusted symptomatic knee osteoarthritis sample as it was 
necessarily similar to subjects that were healthy enough to undergo a major 
surgical procedure. Our results for the non-knee replacement subjects therefore 
should not be used to characterize the participation status of other symptomatic 
knee osteoarthritis subjects. While a clinical trial of knee replacement outcomes 
is not likely given the potential lack of equipoise, other observational studies may 
be conducted that include variables that have yet to be previously studied.  
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The MOST and OAI cohorts have different clinic visit patterns, which could have 
biased results if times to outcome assessments differed. While there could have 
been differences between matched sets, we attempted to control for any 
differences within them. To address this in the crude analysis, we matched 
subjects by baseline visit and study cohort to equate the time from covariate and 
baseline participation assessment to the KR date. For the matched analysis, we 
matched by propensity score within each cohort, and also by the outcome visit.  
Conclusion: There appears to be a protective effect of knee replacement on 
participation among persons with symptomatic knee osteoarthritis. Males, 
younger subjects and those without depressive symptoms have the greatest 
likelihood of success related to participation after knee replacement. Non-White 
subjects and persons with depressive symptoms have the most likelihood of 
having participation restrictions in either knee replacement group. Therefore, 
further study is necessary to identify whether and how participation may be 
increased in these patients, as well as among those with symptomatic knee 
osteoarthritis. 
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Table 3.1. Variables associated with knee replacement and retained in 
propensity score model 
Multicenter Osteoarthritis Study The Osteoarthritis Initiative 
Age Age 
Sex Sex 
Race Race 
Employment/Income Employment/Income 
Depressive symptoms Depressive symptoms 
Use of analgesics Use of knee pain medication 
Use of COXII inhibitors Use of COXII inhibitors 
Worse WOMAC total score Worse WOMAC pain 
Participation Worse WOMAC function 
Worse WOMAC Physical Function  Use of narcotics 
Clinic Site History of high glucose 
Educational attainment Use of chondroitin 
Marital status Diabetes 
Presence of widespread pain Heart failure 
Pack year history of smoking Knee injection 
SF-12 role physical score Stroke 
Systolic Blood Pressure BMI 
Knee flexion strength Diastolic blood pressure 
 Systolic blood pressure 
 SF-12 role physical score 
 SF-12 role mental score 
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Table 3.2. Baseline demographic and clinical information for knee replacement 
(KR) and non- knee replacement (Non-KR) subjects, by matching approach 
 
 
Unadjusted Sample* Propensity Score** Matched Sample 
Variable KR subjects (n=371) 
Non- KR 
subjects 
(n=1484) 
KR 
subjects 
(n=331) 
Non-KR 
subjects  
(n=331) 
Age, years, mean (SD) 
       % < 65 years 
66.6 (8.0) 
40.2 
63.8 (8.4) 
53.8 
66.6 (8.0) 
41 
66.8 (7.9) 
39 
% Female 63 63 63 61 
% White 85.7 76.4 86 86 
BMI, kg/m
2
, mean (SD) 31.3 (6.1) 31.4 (6.0) 31.2 (5.9) 31.2 (5.9) 
Depressive score, mean 
(SD) 
7.5 (7.1) 
 
 
8.0 (8.2) 7.2 (6.9) 
          
7.3 (6.7) 
           
% with ≤ 1 Comorbidity 72.8 76.4 100 100 
Knee pain, range 0-20, 
mean (SD) 
7.8 (3.9) 6.8 (3.6) 6.2 (4.6) 5.9 (4.3) 
Participation, mean (SD) 72.4 (13.6) 74.2 (15.1) 73.4 (13.2) 72.6 (14.2) 
*Matched by baseline visit only 
**Matched on variables listed in propensity score model 
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Table 3.3. Adjusted mean participation, overall and stratified by potential 
confounding and modifying variables 
 Unadjusted Sample Propensity Score Matched Sample 
Knee 
Replace-
ment 
Non-
knee 
replace-
ment 
Mean 
Difference 
(95% CI) 
Knee 
Replace-
ment 
Non-knee 
replace-
ment 
Mean 
Differ-
ence 
(95% CI) 
Overall  74.8 73.3 1.6 (-0.18, 3.3) 
75.2 
(73.6, 76.9) 
73.0 
(71.4, 74.6) 
2.2  
(-0.11, 
4.4) 
Sex Female 73.1 71.5 1.5 (-0.68, 3.7) 
77.6 
(74.9, 80.3) 
75.2 
(72.6, 77.9) 
2.3  
(-1.4, 6.1) 
 Male 77.8 76.2 1.6 (-1.2, 4.5) 
73.6 
(71.6, 75.6) 
71.7 
(69.6, 73.7) 
1.9  
(-0.91, 
4.8) 
Race White 75.8 74.5 1.3 (-0.6, 3.2) 
76.2 
(74.5, 77.9) 
74.0 
(72.2, 75.8) 
2.2  
(-0.31, 4.6 
 Non-White 68.8 69.1 
-0.26 
(-4.8, 4.3) 
68.7 
(64.8, 72.7) 
66.3 
(62.2, 70.4) 
2.5  
(-3.1, 8.1) 
Age 
Category < 65 75.2 73.3 
1.9 
(-0.74, 4.6) 
75.4 
(72.7, 78.0) 
72.1 
(69.7, 74.6) 
3.2  
(-0.36, 
6.8) 
 ≥65 74.6 73.2 1.4 (-1.0, 3.8) 
75.0 
(73.0, 77.1) 
73.5 
(71.4, 75.7) 
1.5  
(-1.5, 4.5) 
Comor-
bidity ≤1 76.7 75.0 
1.6 
(-0.4, 3.6) 
75.5 
(73.7, 77.2) 
73.9 
(72.1, 75.7) 
1.5  
(-0.96, 
4.0) 
 >1 70.1 67.9 2.2 (-1.1, 5.6) NA NA 
NA 
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Persis-
tent Pain Yes 72.8 71.9 
0.9 
(-1.5, 3.3) 
73.0 
(70.5, 75.5) 
71.3 
(69.0, 73.5) 
-1.7  
(-1.6, 5.1) 
 No 76.7 75.1 1.7 (-0.9, 4.2) 
76.4 
(74.3, 78.5) 
75.0 
(72.5, 77.4) 
1.4  
(-1.8, 4.6) 
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Table 3.6. Association between knee replacement and participation restriction 
adjusting for variables associated with both exposure and outcome* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adjusted for age, sex, race, body mass index, depressive symptoms, knee pain, 
number of comorbidities. 
 
Variable Level RR (95% CI)* 
Total  0.83 (0.58, 1.19) 
Sex Female 0.72 (0.48, 1.07) 
 Male 1.25 (0.58, 2.70) 
Race White 0.74 (0.52, 1.07) 
 Non-White 3.77 (0.53, 26.90) 
Age category <65 0.68 (0.72, 1.48) 
 65+ 1.09 (0.66, 1.79) 
# Comorbidities 0-1 0.77 (0.50, 1.20) 
 >1 0.99 (0.53, 1.86) 
Depressive 
Symptoms Yes (>=16) 1.34 (0.75, 2.39) 
 No 0.68 (0.45, 1.04) 
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Figure 3.1. Overlap of propensity scores for knee replacement (top) and non-
knee replacement (bottom) subjects in MOST cohort: i. prior to matching ii. 
following matching                                                                                    
 i.                   ii.   . 
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Figure 3.1b. Overlap of propensity scores for knee replacement (top) and non-
knee replacement (bottom) subjects in OAI cohort: i. prior to matching ii. following 
matching 
 
i.      ii.                     
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Figure 3.2. Trajectories of participation* by knee replacement group over time in 
MOST cohort (a. baseline visit matched b. propensity score matched) 
                                                                                   
a.     
        
b.  
          
        *Mean score, range 0-100. Scale shown 64-84 
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4. The association of knee replacement with all-cause mortality among 
persons with knee osteoarthritis 
 
4.1 INTRODUCTION 
Knee osteoarthritis is a leading cause of disability1, which is associated 
with morbidity and mortality. Currently, knee replacements are the only known 
effective long-term intervention for end-stage knee osteoarthritis. Following 
evidence suggesting that osteoarthritis is an independent predictor of mortality2, 
the question of whether total knee replacement (KR) may decrease the risk of 
mortality has recently been raised in the literature3,4. It is hypothesized that KR 
would have a favorable effect on mortality, likely through promoting increased 
mobility5 and activities of daily living6.   One study of long-term survival after KR 
found no differences in death rates between KR and age and sex matched 
subjects from the general population that did not undergo a KR, however the KR 
subjects lived longer than those without KR7. Conversely, a more recent study3 
reported an excess standardized mortality rate of 1.90 over ten years among 
knee replacement patients compared with the general population.  
Studying this question is methodologically challenging, partially due to the 
difficulty in accounting for confounding by indication. Patients undergoing knee 
replacement could be considered healthier than those with knee osteoarthritis 
who do not have a knee replacement. Surgeons may choose not to perform the 
procedure on patients that might be at risk for poor outcomes from clinical or 
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medical reasons. In particular, to be eligible for surgery, KR patients may have 
less chronic disease, such as diabetes or cardiovascular disease. Studies such 
as the ones discussed above3,7 estimated their measures of effect by comparing 
death rates among those with KR to rates in people from the general population 
matched only by age and sex, leaving open the possibility that confounding by 
indication could explain any differences in mortality. 
 Recently, a study investigating the risk of joint replacement status on 
serious cardiovascular events, including death, among patients with osteoarthritis 
attempted to minimize the effect of confounding by indication by matching on 
propensity score4. They reported that KR subjects had a lower risk of severe 
cardiovascular events, including cardiovascular related deaths, than the non-KR 
subjects.  However, their propensity score matching method included matching 
on the presence of broad diagnoses rather than disease severity, and could 
therefore still contain some residual confounding if the non-KR subjects had less 
severe disease. In addition, they used a landmark analysis where they did not 
include events within three years of KR, which could lead to immortal time bias. 
The purpose of the current study was to determine whether there was an 
association between KR and risk of mortality in persons with knee osteoarthritis 
(KOA).  We were particularly interested in whether there were differences in 
survival for persons with chronic disease (i.e. hypertension (HTN), diabetes, and 
cardiovascular disease) compared to those without, as improved mobility may 
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have a greater effect on their outcomes and because these diseases are strongly 
associated with death. We used data from a large general population database, 
and hypothesized that KR was associated with lower risk of all-cause mortality 
compared with those without KR among persons with KOA. 
4.2 METHODS 
4.2.1 Data Resource 
Our study population consisted of patients with records in the Clinical Practice 
Research Datalink (CPRD) between 1990 and 2012. The CPRD is a population-
based primary care database of patients from the United Kingdom whose general 
practitioners (GP) agree to enter and provide data via codes, for research 
purposes.  Data include demographic, lifestyle, prescription, and clinical 
information. Our study population included subjects 18 to 80 years old who had a 
first knee osteoarthritis (KOA) or knee arthritis (KA) code entered at least 2 years 
after entry into the database. This time window allowed us to capture subjects 
with incident KOA and to allow a two-year baseline covariate assessment period. 
Subjects needed to have at least one activity record after their first knee arthritis 
diagnosis. As we wished to restrict our population to subjects with osteoarthritis 
of the knee, subjects with a KA code but without a KOA code and with a recorded 
history of rheumatoid arthritis, polymyalgia rheumatica, gout, lupus, or psoriatic 
arthritis were excluded. Eligible subjects could not have had a KR in either knee 
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prior to cohort entry. We hand reviewed records of KOA subjects with the above 
codes to validate the selection criteria. 
4.2.2 Study Design 
We conducted a cohort study of KOA subjects from the CPRD. Cohort entry was 
defined as the date of the first KOA or KA diagnosis code. The exposed subjects 
were those with a KR code recorded after cohort entry, while the unexposed 
subjects had no record of KR. The index date for each KR exposed subject was 
the date their KR was recorded. The index date for the non- KR subjects was a 
randomly selected date between the time of cohort entry until censoring. We 
restricted our sample to subjects less than 80 years old at the index date, as 
subjects older than 80 at the time of knee replacement are likely to have different 
risks of mortality and response to surgery than younger subjects, and different 
factors influencing their selection for surgery. We also excluded from our sample 
subjects with diseases that might “contraindicate” KR surgery due to their high 
surgical risk, or with a low frequency and/or high likelihood of confounding in our 
sample (cancer, neuromuscular disease, rheumatic fever, hypotension codes 
(e.g. orthostatic hypotension, idiopathic hypotension), thrombotic disease codes 
(e.g. embolism and thrombosis of a leg artery, aortoiliac obstruction), and liver 
disease).  
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4.2.3 Measurement of Variables 
4.2.3.1 Exposure  
The exposure of interest was KR. All subjects with a primary KR code recorded 
on or after the date the first KOA or KA code was recorded were classified as 
exposed.  Patient records were reviewed to confirm correct diagnosis for 
validation purposes (discussed above). Exposed subjects may have had one or 
both knees replaced during the study period, and may have had revision KR 
procedures. 
4.2.3.2 Outcome 
The outcome of interest in this study was death and was assessed with all-cause 
mortality rates and hazard of death. Recording of incident death in CPRD has 
been externally validated8. Follow-up time began at the index date (defined 
above). Subjects were censored at death, transfer out of the practice or the date 
of last data update, whichever came first.  
4.2.3.3 Covariates:  
We collected data on date of birth, sex, body mass index (BMI) and smoking 
status. When a BMI value was not available in the patient record, we calculated 
BMI from height and weight records using the formula kg/m2 where present.  We 
used information in the record closest to the index date within one year before, 
and if not available prior, then up to 6 months after the index date. If a specific 
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value for height and/or weight was unavailable then BMI was coded as unknown 
(<2% of subjects). Smoking status was defined as current, never, former or 
unknown. We used the status recorded closest to the index date up to 2 years 
prior, or if not available, up to 1 year after. We collected data on the presence of 
other comorbid conditions besides HTN, Type II diabetes (DM), and 
cardiovascular disease or those previously restricted prior to the index date: 
congestive heart failure, cognitive illness, depression, infection, kidney disease, 
mental illness, peripheral vascular disease, pulmonary disease, and 
gastrointestinal disease. 
We also attempted to control for the overall health of the study population using 
the following algorithms related to the three large chronic disease groups of 
interest:  HTN, DM, and cardiovascular and cerebrovascular disease (CVD). We 
required subjects to have both a diagnosis code and a treatment code in their 
record to be classified as having HTN.  We constructed a HTN severity variable 
based on the number and class of medications used within 6 months prior to the 
index date and whether the subjects had a record of systemic hypertensive 
complications. Patients on only one anti-hypertensive medication were classified 
with a score of 1, while those on more than one drug or a combination of first-line 
drugs, or with a higher class drug were scored as 2.  Patients with hypertensive 
complications were scored as 3. We classified patients as diabetic (DM) if they 
met our definition of Type II diabetes based on the following algorithm:  there was 
record of a Type II or non-insulin dependent code, or a general diabetes code 
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with either an oral hypoglycemic treatment code or with no drug treatment code. 
Then, for those subjects, we assigned a severity score of 1 or 2 based on the 
presence and type of complications using the Diabetes Complications Severity 
Index9, as DM complications have been more closely associated with mortality 
than treatment9. Patients with no diabetic complications were scored 0, those 
with complications such as skin, foot and/or ocular complications were scored 
with a 1, while those with ketoacidosis, coma, or gangrene were scored as 2. 
 For CVD, we generated categories of diagnoses and procedures to allow fine 
control of differences between groups and to have the ability to sum the 
presence of multiple diagnoses. We created four categories of cardiac 
procedures (heart valve, revascularization, pacemaker-related, and other). We 
also categorized diagnoses into 10 groups (arrhythmias, atherosclerosis, 
myocardial infarctions, ischemic heart disease, endocarditis (infections), 
aneurysms, valve-related diagnoses, cerebrovascular disease, cerebrovascular 
accidents (stroke), and transient ischemic accidents or transient cerebrovascular 
infarcts).  Finally, we attempted to characterize the magnitude of CVD 
involvement by creating a variable representing the number of CVD diagnoses 
and/or procedures for each subject. 
Aside from general health, severity of KOA disease is also a potential confounder 
of the association of knee replacement and mortality as it has been associated 
with both10,11. While the CPRD does not have consistent radiologic data to allow 
conventional radiographic classification of osteoarthritis disease severity, or data 
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on knee pain severity, it does have comprehensive prescription data and 
referrals to specialists. We therefore created a KOA severity index from 
medication class variables based on the American College of Rheumatology 
guidelines for the treatment of KOA11 and the presence of at least one code 
indicating referral to a specialist, such as a rheumatologist, orthopedist, or 
physiotherapist (Table 4.2).  
4.2.4 Statistical Analysis 
We calculated crude death rates for each exposure group and stratified them by 
sex, age (less than or greater than or equal to 65 years), and presence or 
absence of HTN, DM, or CVD. We checked for proportional hazards of death by 
exposure group using the ph assess statement in SAS 9.3. We used a modified 
Cox Proportional Hazard model12 to estimate the hazard ratio and 95% 
confidence interval for mortality, then repeated our analyses with multiple models 
adjusting for combinations of demographic and chronic disease status and 
severity. We then stratified by intervals of time since the index date.  Additionally, 
we calculated propensity scores for all subjects’ probability of receiving a knee 
replacement based on their individual covariate profiles. Then, we matched one 
KR subject to one non-KR subject by their propensity score using greedy 
matching methods13. This created a new study population from which we 
repeated our modified Cox proportional hazard models. Since this population 
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was matched by propensity score which accounted for the subjects’ covariate 
profiles, we did not adjust for any other variables in these models.  
Finally we assessed the effect of KR status on the development of new disease 
(cancer, HTN, DM and CVD) after the index date by calculating incidence rates, 
rate differences, and rate ratios. These analyses were performed to assess 
potential relationships that may be present along the biologic pathway from KR 
status to mortality, and therefore will help interpret the results. For example, a 
decrease in the incidence of hypertension may suggest a decrease in risk factors 
for hypertension, such as obesity or lack of physical activity. All analyses were 
conducted using SAS 9.3 (Cary, NC). 
4.3 RESULTS  
The study population comprised 126,683 subjects with KOA. After excluding 
subjects with “contraindicated” diseases our sample included 14,624 knee 
replacement subjects and 76,289 non-knee replacement subjects (Figure 1). 
1,855 (12.7%) KR subjects and 12,017 (15.8%) non-KR subjects died during the 
study period. The distribution of the index dates for the unmatched sample were 
similar for each exposure group, with increased index dates later in the follow up 
time as expected (see A4.1) There was one spike in the table with an increased 
incidence of index dates in 2010 for the non-KR subjects. Table 1 displays the 
demographic and clinical characteristics of the subjects in each exposure group. 
The knee replacement subjects were older, more likely to be overweight or obese 
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and were less likely to be current smokers than the non-knee replacement 
subjects. They also had predictably higher KOA severity scores. The proportions 
with HTN were higher for the KR subjects compared with the non-KR subjects in 
the younger (< 65 years old) group (35% vs. 22%), but were similar for the older 
group (44% vs. 42%, respectively). The groups were consistently similar with 
respect to prevalence and severity of other chronic diseases and cardiovascular 
procedures. As the number of subjects with the moderate and severe HTN and 
DM categories was small, we collapsed the two categories into a “moderate-
severe” group for our analyses. The distributions for the time from the covariate 
assessment and the index date were similar for the KR and non-KR subjects 
(example for BMI shown in A4.2).  
The death rates were higher for older subjects than younger subjects, across all 
demographic and chronic disease categories as expected. Similarly, within each 
age category, the death rates were higher for those with each disease as 
compared to those without. Finally, in each stratum, the death rates for the KR 
subjects were consistently lower than those of the non-KR subjects. The 
magnitude of the differences in death rates between the KR and non-KR subjects 
for each disease was smaller among the younger subjects as compared to the 
older subjects. (See Tables 4.3 and 4.4). 
The hazard of death did not meet the proportional hazard assumption (Figure 
4.2). The graph displaying the hazard over time suggested that it changed every 
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5 years after the index date, thus we conducted separate adjusted analyses for 
0-5 years, 5-10 years, and 10+ years after the index date (Table 4.6). There was 
a reduction in the hazard of death for KR subjects as compared to the non-KR 
subjects, with the lowest hazard ratio during the first five years after the index 
date (HR 0.39, 95% CI 0.37, 0.42). The risk of death was reduced for KR 
subjects within all strata of sex and age groups over the first five years after the 
index date (Table 4.5). There was effect measure modification by age and sex, 
with the hazard of death being lower for the older subjects than for the younger 
subjects (HR 0.41 vs. 0.48) and for females compared with males (0.37 vs. 0.51). 
For the younger subjects and both females and males, the effect of KR on 
mortality was strongest when adjusting for the presence and severity of HTN, 
alone, or in combination with the other chronic diseases. There were no 
appreciable differences in the magnitude of the protective effects in the older 
subjects when stratified by other concomitant disease. The protective effect of 
KR on mortality appeared to attenuate after the first five years after the index 
date (Table 4.6), and among the younger age group the effect became null after 
5 years. 
We calculated the propensity for receiving a knee replacement based on each 
subjects’ covariate data for the same 35 covariates that were included in the 
adjusted Cox models (listed at bottom of Table 4.5). After matching, there were 
12,823 subjects in the KR exposed and unexposed groups. There were 1,801 KR 
subjects that could not be matched to a non-KR subject because their propensity 
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scores were either too high or too low to be matched using the greedy matching 
algorithm. In general, the KR patients that did not receive a match were healthier 
than those that did receive a match. Although the mean age in these KR subjects 
was older (70.6 years at index date) than those that were included in the 
matched sample, there were fewer women (53%) , almost all had a normal BMI, 
23% had HTN, 18% had CVD and less than 2% had DM.  The match resulted in 
a sample of KR subjects who had higher proportions of chronic disease 
compared to the whole study population, but who were more similar to the non-
KR exposed patients. The Cox models were again estimated for 0-5, 5-10 and 
10+ years after the index date to account for lack of proportional hazards. These 
data similarly show a protective effect for KR on mortality compared with the non-
KR subjects in the first five years (HR 0.42, 95% CI 0.40, 0.43), which attenuated 
over time (Table 4.7). In the younger subjects, the protective effect disappeared 
10 years post-index date (HR 0.90, 95% CI 0.70, 1.1). The effect weakened but 
persisted at 10+ years post-index date for the older subjects (HR 0.70, 95% CI 
0.62, 0.70).  
The results differed depending on the decile of propensity score (i.e. one’s 
likelihood of having a KR based on their individual covariates) (Table 4.8). There 
was no effect of KR on mortality among the subjects in the two deciles with the 
lowest propensity scores (lowest probability of having KR; i.e., least healthy), 
even in the first five years (decile 1, HR 0.64, 95% CI 0.37, 1.1). Among the other 
deciles, the protective effect appeared only in the first five years.  
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We looked at the relative risk of cancer and other illnesses in the KR cohort 
compared to the non-KR cohort in order to help understand the mechanism 
behind any effect on mortality. If KR improves mobility as hypothesized, we 
would expect a reduction in diseases highly associated with activity, such as 
HTN and CVD, while we would not expect to see an effect on the incidence of 
cancer. Table 4.9 displays the incidence rates and rate ratios for cancer, HTN, 
DM and CVD after the index date for the propensity score matched subjects. 
There was a reduction in risk of incident CVD for the KR subjects as compared to 
the non-KR subjects (IRR 0.87, 95%CI 0.83, 0.92), although there was no 
association with cancer, HTN or DM. 
4.4 DISCUSSION 
In this study of risk of mortality among subjects with KOA, the death rate among 
KR subjects was lower than the rate among non-KR subjects, and the hazard of 
death was reduced by greater than half for KR subjects in the first five years after 
the index date. We found effect modification by age and sex, with older subjects 
and females receiving a greater benefit than their counterparts, and by time, 
where the benefit tended to occur mainly in the first five years after the 
procedure. The results from the analyses of the whole sample and those from the 
propensity score matched sample were similar, however our propensity matched 
results demonstrated differences in risk of mortality according to health status 
prior to the index date. 
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This study was the first, to our knowledge, to discover and report a change over 
time in the hazard ratio of death following KR. The proportional hazards 
assumption was not met, and the protective effect of KR was eliminated or 
decreased after the first five years following the index date. Our results 
underscore the difficulty in assessing the relationship between a surgical 
procedure in an aging patient population and the risk of all-cause mortality.  
Our study design attempted to minimize the potential for confounding by 
indication through the use of disease severity algorithms, restriction, and 
propensity score matching. Previous studies have also reported a protective 
effect of knee replacement on mortality, however, in these studies there was 
potential for selection bias where the KR subjects may have been healthier than 
the non-KR subjects due to the selection of general population comparison 
groups or less rigorous methods to minimize bias. We demonstrated that the 
subjects in our two KR exposure groups, even before matching, were similar with 
respect to the prevalence and severity of chronic diseases, including HTN, DM 
complications and cardiovascular diseases, and number of events and 
procedures. Furthermore, by matching on propensity score we were able to 
estimate the effect of KR status and mortality on subjects matched by their 
likelihood of receiving the exposure, and among subgroups of subjects with 
differing levels of this likelihood. 
Given the similarities between our exposure groups, there are two primary 
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potential interpretations of our results. The first supports the hypothesis that KR 
can reverse the impact of chronic disease by increasing mobility and participation 
in community activities, thereby improving longevity. We were unable to fully 
investigate this mechanism with the current data, although the protective rate 
ratio for incident cardiovascular disease favoring KR subjects may support this 
hypothesis. Further evidence includes the observation that the protective effect of 
KR was stronger and lasted longer among the older subjects. This may be 
attributed to the larger absolute risk of death in older patients, which provides 
more opportunity for greater benefit. Additionally, the subjects with the lowest 
propensity scores received no protective effect, possibly because they were too 
sick to restore health. Even so, the loss of the overall protective effect after the 
first five years suggests that the benefit is time limited, or could be attributed to 
another source.   
The other leading interpretation is that residual confounding is present, 
particularly biasing the results in the first five years after the procedure. Given 
that the reported effect is slightly stronger than what has been seen from an 
increase in physical activity14, it is possible that an unmeasured factor or 
combination of factors not evaluated in our study resulted in a decision against 
KR for those with a greater risk of death or to choose KR if very healthy. For 
example, the effect measure modification whereby the older subjects had a 
stronger protective effect could signal confounding by indication if only the most 
robust older patients were selected for surgery. 
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 This unmeasured factor could be the surgeons’ ability to predict imminent 
morbidity or mortality in the next 5 years based on their patients’ medical record 
and clinical presentation. This could lead them to avoid surgery in some people 
and could account for the presumed stronger effect over the first 5 years. The 
impact of aging and the possibility of developing new illnesses may reasonably 
diminish the surgeons’ ability to predict death further than 5 years out.  We are 
aware of another group that found a greater protective effect of KR on mortality 
among the subjects with the highest propensity scores (presumed healthiest) 
(data not yet published). This is consistent with our results, where those with the 
highest scores had a greater protective effect and the “least healthy” had no 
protective effect.  
In addition to the potential for residual confounding, there are some limitations to 
this study. Subjects who had mild KOA may have been missed (misclassified as 
not having KOA), and therefore under-represented in our study population. We 
examined patient records to validate the code list used to classify subjects as 
having KOA, however it is possible that some mild cases did not receive a KOA 
code. The severity code algorithm allowed us to control for disease severity in 
our analyses, however we may not be able to address the benefits of KR among 
people with mild KOA.   Another limitation is the absence of information on some 
potential risk factors. For example, we could not fully assess KOA severity or the 
presence of bilateral disease. Consistent with other literature, the KOA severity 
variable we constructed was associated with both KR status and mortality2,10 and 
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we used clinical guidelines to construct our KOA severity variable11. However, as 
KOA severity did not change the estimate of effect, it is unlikely that additional 
information on KOA status would have materially changed our results. It is further 
possible that the presence of bilateral or revision KR procedures may have 
impacted our results either positively or negatively, but reliable information was 
not available and we were not able to control for these procedures. Our design 
attempted to minimize immortal time bias by starting the follow up time at the 
index date (exposure) rather than the date of KOA diagnosis.  By shortening the 
follow up time this approach increased the death rates in both exposure groups, 
yet the ratios between the groups should be preserved.  
CONCLUSION 
 Despite attempts to minimize confounding by indication, this study found a 
protective effect on mortality over the first five years following the procedure, 
even in the presence of severe chronic disease. However, it continues to be 
possible that an unmeasured confounder may be responsible for the effect as not 
all subject groups received this benefit. 
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Table 4.1. Characteristics of exposed and unexposed patients with knee 
osteoarthritis, stratified by knee replacement status  
Variable Level No. (%) 
 Variable Knee Replacement                    
Subjects n=14,624 
(%) 
Non Knee 
Replacement Subjects 
n=76,289 (%) 
Sex: 
 
Female 
Male 
8436 (58) 
6188 (42) 
44893 (59) 
31396 (41) 
Age: 
 
Mean (SD) 
% < 65 
% ≥65 
69.9 (9.0) 
4057 (28) 
10567 (72) 
67.3 (12.9) 
32107 (42) 
44182 (58) 
BMI category: 
 
<25 
25-29.9 
30-34.9 
≥35 
3467 (24) 
5010 (34) 
3846 (26) 
2301 (16) 
23780 (31) 
25282 (33) 
16227 (21) 
11000 (14) 
Smoking status: 
 
Never 
Former 
Current 
Unknown 
7478 (51) 
5553 (38) 
1229 (8) 
364 (2) 
37630 (49) 
25765 (34) 
104 (14) 
2423 (3) 
Hypertension 
(HTN) 
 
Total % of sample 
Severity index =1 
Severity index =2 
Severity index=3 
6617 (42) 
1615 (24) 
4810 (73) 
76 (1) 
27637 (34) 
6867 (25) 
19332 (70) 
384 (1) 
Cardiovascular 
Disease (CVD) 
 
Total % of sample 
Arrhythmia 
Atherosclerosis 
Myocardial infarction 
Ischemic heart disease 
Endocarditis 
Aneurysm 
Valve disease 
Cerebrovascular 
disease 
Stroke 
Transient ischemic 
attack 
3785 (24) 
1345 (9) 
1614 (10) 
623 (4) 
 
1334 (8) 
17 (0) 
4 (0) 
175 (1) 
 
439 (3) 
410 (3) 
 
477 (3) 
19905 (25) 
7458 (9) 
8348 (10) 
3505 (4) 
 
7409 (9) 
85 (0) 
18 (0) 
1063 (1) 
 
2972 (4) 
2793 (3) 
 
2836 (3.5) 
Cardiac 
Procedures: 
 
Revascularization 
Valve procedures 
Pacemaker 
Other: 
473 (3) 
65 (0) 
73 (0.5) 
74 (0.5) 
2172 (3) 
398 (0) 
449 (0.6) 
497 (0.6) 
Type II Diabetes 
(DM) 
 
Total % of sample 
Severity index=1 
Severity index=2 
1664 (11) 
 307 (18.4) 
322 (3.4) 
9273 (11)  
1836 (19.8) 
378 (3.5) 
Depression 2381 (15) 14097 (17) 
Mean no. other comorbidities (SD) 0.66 (0.84) 0.75 (0.91) 
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Table 4.2. KOA severity index† and proportions of subjects in each category, by knee 
replacement group 
Severity 
Index† 
Medications % KR 
Subjects 
% non-KR 
Subjects 
0 No record of medications <1 7 
0.5 Score of 0 and “referred”‡ <1 <1 
1 Acetaminophen, topical pain 
medications, aspirin <1 2 
1.5 Score of 1 and referred <1 <1 
2 Oral NSAIDS, including Cox-II 
inhibitors, injections 4 11 
2.5 Score of 2 and referred 7 5 
3 Opioids, Duloxetine 28 37 
3.5 Score of 3 and referred 58 36 
†Based on Hochberg, 2012 overview for KOA management. ‡“Referred” defined as 
codes in record of referral to specialist, including rheumatology, orthopedics, 
physiotherapy 
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Table 4.7   Risk of mortality by age and time since index date among 12,823 KR 
and 12,823 propensity score matched non-KR patients 
 
Subgroup 0-5 years post-
index 
HR (95% CI) 
5-10 years post-
index  
HR (95% CI) 
10+ years post-
index  
HR (95% CI) 
All subjects 0.42 (0.40, 0.43) 0.70 (0.66, 0.74) 0.76 (0.70, 0.83) 
< 65 years old* 0.43 (0.37, 0.50) 0.70 (0.58, 0.85) 0.90 (0.70, 1.1) 
≥ 65 years old* 0.40 (0.39, 0.42) 0.66 (0.62, 0.70) 0.70 (0.62, 0.70) 
 HR (95% CI) =Hazard ratio (95% confidence interval) 
*At time of index date 
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Figure 4.1. Study Population 
                  
     Qualified KOA/KA Code and No KR before KOA diagnosis,  
                                        <80 years old at index date 
                                                       = 126,683 
  
 
                                       Restricted by “contraindications” 
 
 
                                           Study population= 90,913 
                                               
                                                                     
                              KR Subjects=14,624                  Non-KR subjects=76,289 
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Figure 4.2. Graph of hazard of death for KR and non-KR 
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Appendix 
A4.1 Distribution of index date: (top) non-KR subjects (bottom) KR subjects  
 
 
 
 
 
 
 
  
  96 
A4.2 Distribution of time to BMI assessment for a. KR subjects b. non- KR 
subjects 
a.  
b.  
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